Invivyd, Inc.(IVVD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,521 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
IVVD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Invivyd, Inc. (IVVD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IVVD at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,521 of 2,962 stocks — the bottom half of the AI-ranked universe. IVVD scores in the top quartile across revenue growth (99.3). Areas of concern include balance sheet strength (2.2) and free cash flow (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Invivyd, Inc. reports quarterly revenue of $14.3M, net income of $-44.4M, free cash flow of $-43.5M. Top institutional holders of IVVD by reported 13-F value include Jupiter Topco, BVF, MAVERICK CAPITAL LTD, based on the most recent SEC filings. IVVD trades on the Nasdaq exchange and files with the SEC under CIK 1832038. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IVVD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Invivyd, Inc. directly from SEC EDGAR. Invivyd, Inc.'s 13F Pro composite quality score has ranged between 10 and 31 since 2025, currently 29.7 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$14.3M
Net Income
Q2 2026
$-44.4M
Free Cash Flow
Q2 2026
$-43.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+110.5% YoYNet Income
+69.1% YoYOperating Income
+68.6% YoYEPS (Diluted)
+79.0% YoYTotal Assets
+113.8% YoYOp. Cash Flow
+65.9% YoYFree Cash Flow
+65.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $53.4M +110.5% | $25.4M | $0.00 | — | — | — |
| Net Income | $-52.5M +69.1% | $-169.9M +14.5% | $-198.6M +17.7% | $-241.3M -6.4% | $-226.8M | — |
| Operating Income | $-55.6M +68.6% | $-176.9M +16.9% | $-212.8M +14.2% | $-248.0M -9.3% | $-226.9M | — |
| EPS (Diluted) | $-0.30 +79.0% | $-1.43 +21.0% | $-1.81 +18.8% | $-2.23 +58.1% | $-5.32 | — |
| Total Assets | $276.9M +113.8% | $129.5M -43.5% | $229.2M -40.2% | $383.2M -38.2% | $620.1M +428.3% | $117.4M |
| Operating Cash Flow | $-58.1M +65.9% | $-170.5M +1.5% | $-173.2M +21.3% | $-220.0M -19.1% | $-184.7M | — |
| Free Cash Flow | $-58.3M +65.8% | $-170.6M +1.8% | $-173.8M +21.6% | $-221.7M -20.0% | $-184.8M | — |
Get alerted when IVVD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Invivyd, Inc. including:
Top Institutional Holders of IVVD
Jupiter Topco LLC
$30.0M34,173,104 shBVF INC/IL
$24.6M28,165,000 shMAVERICK CAPITAL LTD
$16.6M18,970,913 shPERCEPTIVE ADVISORS LLC
$16.1M18,490,636 shBlackRock, Inc.
$14.1M16,134,885 shVANGUARD CAPITAL MANAGEMENT LLC
$9.2M10,496,507 shM28 Capital Management LP
$8.1M9,248,250 shSaturn V Capital Management LP
$7.3M8,392,288 shSoleus Capital Management, L.P.
$6.7M7,708,727 shPoint72 Asset Management, L.P.
$6.6M7,542,061 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $30.0M | 34,173,104 |
| BVF INC/IL | $24.6M | 28,165,000 |
| MAVERICK CAPITAL LTD | $16.6M | 18,970,913 |
| PERCEPTIVE ADVISORS LLC | $16.1M | 18,490,636 |
| BlackRock, Inc. | $14.1M | 16,134,885 |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.2M | 10,496,507 |
| M28 Capital Management LP | $8.1M | 9,248,250 |
| Saturn V Capital Management LP | $7.3M | 8,392,288 |
| Soleus Capital Management, L.P. | $6.7M | 7,708,727 |
| Point72 Asset Management, L.P. | $6.6M | 7,542,061 |
Companies Similar to IVVD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Vir Biotechnology, Inc.
Kura Oncology, Inc.
BICYCLE THERAPEUTICS PLC
REGENXBIO Inc.
Viridian Therapeutics, Inc.\DE
Foghorn Therapeutics Inc.
X4 Pharmaceuticals, Inc
Kymera Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put IVVD on your watchlist
Track score changes the day Invivyd, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IVVD a good stock to buy?
13F Pro's AI-powered analysis of Invivyd, Inc. (IVVD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IVVD are available on the IVVD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IVVD is classified as a small company.
Which hedge funds own IVVD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IVVD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Invivyd, Inc.'s investment landscape.